Kalypso Wellness Center Patients See 90 Success Rates

Tuesday, July 23, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

Patients at Kalypso Wellness Center continue to see 90 percent success rates compared to national averages between 60 to 70 percent, expands diseases treated with patent pending formulations

DALLAS, July 23, 2019 /PRNewswire-PRWeb/ -- As Kalypso Wellness Center, one of the nation's leading providers of ketamine

infusions, continue to grow, it's their treatment success rates that are truly astounding. Patients treated at Kalypso experience a 90 percent success rate, compared to national averages that range between 60-70 percent. Perhaps even more impressive is that less than five percent of Kalypso patients experience any side effects such as headaches, grogginess, insomnia, anxiety, nausea, etc.. Kalypso attributes these impressive metrics to their unique protocols and patent pending formulations.

The formulations are also demonstrating success in the treatment of conditions not typically associated with ketamine treatments such as auto-immune disease (Multiple Scleroris, Lupus) as well as Lyme disease and ALS. To date, Kalypso's patent pending ketamine infusions have been utilized in in early 6,000 infusions representing 32 different states including headaches, fibromyalgia, depression and PTSD,

"The ketamine clinic industry continues to grow, with more than 300 ketamine clinics across the country, and more opening each week," explains explains Ryan Bridges, Kalypso Wellness Centers Chief Operating Officer. "While we're excited to see more and more people accepting this new treatment modality, we do have to caution patients to do their research before choosing a clinic."

Once thought of as a street drug, ketamine infusions have become a more accepted method of treatment for patients looking for alternative treatments for depression, anxiety and many other diagnoses. More than 16 million Americans suffer from depression, and 30 percent of them have treatment-resistant depression, driving demand for alternatives to traditional antidepressants. Research has shown that ketamine targets the brain very differently to the current crop of antidepressants.

Dr. Cannon Clifton, Kalypso Wellness Center's CEO and co-founder, cautions people who are looking into ketamine infusions that because the infusions are not yet regulated by the Federal Drug Administration, there are no strict guidelines put in place for these clinics.

The American Psychiatric Association has issued recommendations but in many cases those are not being followed. This can lead to improper oversight of the patient during the infusion, lack of patient follow up and even administering ketamine infusions to patients when it's not medically necessary. This is not the case for patients who visit any of the 8 Kalypso Wellness Center locations in Texas, Pennsylvania, Mississippi, and New York. As one of the nation's leading ketamine infusion providers, Kalypso's approach to this industry is truly unique. They are one of only a handful of companies with multiple locations across the country. Their growing footprint in the ketamine infusion industry is one of the many things that allows them to stay at the forefront of this continually changing industry.

Kalypso Wellness Centers was founded in 2016 by two board-certified anesthesiologists and two board-certified pain management physicians with 50 years of total experience. To date, they have performed more than 6,000 infusions which allows them to continue to fine-tune and optimize their formulations in order to achieve the best results possible. Unlike other ketamine infusion clinics, Kalypso uses five distinct formulations and have the ability to use the patient's own DNA to create a completely customized approach to the patient's symptoms.

About Kalypso Wellness Centers Kalypso Wellness Centers was formed in 2016 by two board certified anesthesiologists Dr. Cannon Clifton, CEO and Dr. Bryan Clifton, CMO; and two board certified pain management physicians, Dr. Mark Moran, Chief Science Officer and Dr. Scott Worrich, Chief Clinical Officer who were tired of seeing patients needlessly suffering and chronically debilitated on prescription narcotics. After countless months of research, they found a promising new solution with the use of ketamine infusions that could be offered to patients. As treatments continued, they created the RESET Ketamine Therapy™, which includes five distinct proprietary ketamine formulations: KalyCalm™, KalyCan™, KalyMax™, KalyPro™ and KalyZen™. Upon further investigation, they discovered that when tailored to each patient's unique disease state, these infusions can provide a substantial improvement in quality of life for patients with anxiety, major depressive disorder, PTSD, bipolar disorder, fibromyalgia, neuropathic pain, inflammatory pain, chronic pain, and migraines/chronic headaches.

For more information, visit [http://www.kalypsowellness.com

 

SOURCE Kalypso Wellness Center



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store